Mast Therapeutics Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
January 7, 2016 12:01 PM ESTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $5 price target on Mast Therapeutics (NYSE: MSTX) noting pivotal data in sickle cell ahead and pipeline progress.
Kolbert highlighted:
Management provided a detailed update, highlighting key clinical and regulatory milestones in 2016 including the status of the pivotal phase III "EPIC" study (N=388) of vepoloxamer in sickle cell disease (SCD). We remain... More


